Table 1

Admission and Hyperinflammation Laboratory Results

Laboratory MeasuresValueReference Range
Admission (HD 0)
 White blood cell count, per μL54704500–13500
 Absolute lymphocyte count, per μL711 (L)1485–6480
 Hemoglobin, g/dL12.312–16
 Platelet count, ×103/μL<10 (L)150–450
 Prothrombin time, s15.312.6–15.9
 Activated partial thromboplastin time, s53.6 (H)26–38
 Fibrinogen, mg/dL424 (H)200–400
 Sodium, mmol/L132 (L)134–143
 Creatinine, mg/dL0.690.30–0.80
 Total bilirubin, mg/dL0.80.2–1.0
 Aspartate aminotransferase, U/L37 (H)17–33
 Alanine aminotransferase, U/L2511–33
 CRP, mg/dL11.5 (H)<1.0
 Procalcitonin, ng/mL0.83 (H)<0.10
 Ferritin, ng/mL481 (H)14–79
HD 4a
 CRP, mg/dL8.3 (H)<1.0
 Ferritin, ng/mL600 (H)14–79
 IL-2 receptor, pg/mL910<1033
 IL-6, pg/mL10 (H)<5
 Interferon-γ, pg/mL<5<5
 IL-10, pg/mL<5<18
HD 7b
 CRP, mg/dL10.3 (H)<1.0
 Ferritin, ng/mL436 (H)14–79
 IL-2 receptor, pg/mL1486 (H)<1033
 IL-6, pg/mL34 (H)<5
 Interferon-γ, pg/mL10 (H)<5
 IL-10, pg/mL9<18
 CXCL9, pg/ml248(H)<121
 IL-18, pg/mL1184 (H)89–540
  • CXCL9, C-X-C motif chemokine 9; H, high; IL-2, interleukin-2; IL-10, interleukin-10; IL-18, interleukin-18; L, low.

  • a Drawn on HD 4.

  • b Drawn before administration of tocilizumab on HD 7.